156 related articles for article (PubMed ID: 7990116)
21. Skeletal conformations and receptor binding of some 9,11-modified estradiols.
Palomino E; Heeg MJ; Horwitz JP; Polin L; Brooks SC
J Steroid Biochem Mol Biol; 1994 Jul; 50(1-2):75-84. PubMed ID: 8049136
[TBL] [Abstract][Full Text] [Related]
22. A comparative molecular field analysis (CoMFA) study using semiempirical, density functional, ab initio methods and pharmacophore derivation using DISCOtech on sigma 1 ligands.
Jung D; Floyd J; Gund TM
J Comput Chem; 2004 Aug; 25(11):1385-99. PubMed ID: 15185333
[TBL] [Abstract][Full Text] [Related]
23. A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding affinities of structurally diverse compounds.
Waller CL
J Chem Inf Comput Sci; 2004; 44(2):758-65. PubMed ID: 15032558
[TBL] [Abstract][Full Text] [Related]
24. CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists.
Datar P; Desai P; Coutinho E; Iyer K
J Mol Model; 2002 Oct; 8(10):290-301. PubMed ID: 12483229
[TBL] [Abstract][Full Text] [Related]
25. 3D-QSAR based on quantum-chemical molecular fields: toward an improved description of halogen interactions.
Güssregen S; Matter H; Hessler G; Müller M; Schmidt F; Clark T
J Chem Inf Model; 2012 Sep; 52(9):2441-53. PubMed ID: 22917472
[TBL] [Abstract][Full Text] [Related]
26. 3D QSAR based design of novel oxindole derivative as 5HT7 inhibitors.
Chitta A; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Jun; 34(3):185-94. PubMed ID: 24456291
[TBL] [Abstract][Full Text] [Related]
27. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
Oloff S; Mailman RB; Tropsha A
J Med Chem; 2005 Nov; 48(23):7322-32. PubMed ID: 16279792
[TBL] [Abstract][Full Text] [Related]
28. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
29. Modification of polychlorinated phenols and evaluation of their toxicity, biodegradation and bioconcentration using three-dimensional quantitative structure-activity relationship models.
Tong L; Guo L; Lv X; Li Y
J Mol Graph Model; 2017 Jan; 71():1-12. PubMed ID: 27825025
[TBL] [Abstract][Full Text] [Related]
30. Quantitative structure-activity relationships (QSARs) for estrogen binding to the estrogen receptor: predictions across species.
Tong W; Perkins R; Strelitz R; Collantes ER; Keenan S; Welsh WJ; Branham WS; Sheehan DM
Environ Health Perspect; 1997 Oct; 105(10):1116-24. PubMed ID: 9353176
[TBL] [Abstract][Full Text] [Related]
31. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
[TBL] [Abstract][Full Text] [Related]
32. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
33. Comparison of electrotopological-state indices versus atomic charge and superdelocalisability indices in a QSAR study of the receptor binding properties of halogenated estradiol derivatives.
Ghafourian T; Cronin MT
Mol Divers; 2004; 8(4):343-55. PubMed ID: 15612638
[TBL] [Abstract][Full Text] [Related]
34. Three-dimensional quantitative structure--activity relationships for androgen receptor ligands.
Waller CL; Juma BW; Gray LE; Kelce WR
Toxicol Appl Pharmacol; 1996 Apr; 137(2):219-27. PubMed ID: 8661347
[TBL] [Abstract][Full Text] [Related]
35. 11 beta-Substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity relationship study.
Napolitano E; Fiaschi R; Carlson KE; Katzenellenbogen JA
J Med Chem; 1995 Feb; 38(3):429-34. PubMed ID: 7853335
[TBL] [Abstract][Full Text] [Related]
36. 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach.
Zhang Z; An L; Hu W; Xiang Y
J Comput Aided Mol Des; 2007 Apr; 21(4):145-53. PubMed ID: 17203365
[TBL] [Abstract][Full Text] [Related]
37. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
38. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
[TBL] [Abstract][Full Text] [Related]
39. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
Babu S; Sohn H; Madhavan T
Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
[TBL] [Abstract][Full Text] [Related]
40. Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via comparative molecular field analysis.
Huang Q; Liu R; Zhang P; He X; McKernan R; Gan T; Bennett DW; Cook JM
J Med Chem; 1998 Oct; 41(21):4130-42. PubMed ID: 9767648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
